(R)-6,7,8,9-tetrahydro-5H-benzocyclohepten-6-amine | 101692-74-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (R)-6,7,8,9-tetrahydro-5H-benzocyclohepten-6-amine
• 英文别名: (R)-6,7,8,9-Tetrahydro-5H-benzocyclohepten-6-ylamine；(6R)-6,7,8,9-Tetrahydro-5H-benzo[7]annulen-6-amine
• CAS: 101692-74-4
• 化学式: C₁₁H₁₅N
• 分子量: 161.247
• InChiKey: MDVRGZASGHPBAG-LLVKDONJSA-N

物化性质

• 沸点：
  270.0±19.0 °C(Predicted)
• 密度：
  0.997±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (R)-6,7,8,9-tetrahydro-5H-benzocyclohepten-6-amine 生成 (R)-(+)-4-BROMO-N-(6,7,8,9-TETRAHYDRO-5H-BENZOCYCLOHEPTEN-6-YL)-BENZAMIDE
  参考文献：
  名称：

  Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical agents

  摘要：

  本发明涉及符合一般式（I）的化合物，其中R1-R4具有描述中给出的含义，A为CH2，CHOH或CH-（C1-C3-烷基），B、C和D分别为CH2或CH-（C1-C3-烷基），R5为芳基或杂芳基，可能被描述中列出的取代基取代。这些化合物可用于制造治疗心血管疾病、稳定或不稳定性心绞痛、冠心病、普林兹梅塔尔心绞痛、急性冠状动脉综合征、心力衰竭、心肌梗死、中风、血栓形成、周围动脉闭塞性疾病、内皮功能障碍、动脉粥样硬化、再狭窄、PTCA后内皮损伤、高血压、原发性高血压、肺动脉高压、继发性高血压、肾血管性高血压、慢性肾小球肾炎、勃起功能障碍、室性心律失常、糖尿病、糖尿病并发症、肾病、视网膜病变、血管生成、支气管哮喘、慢性肾功能衰竭、肝硬化、或受限的记忆表现或受限的学习能力，或降低绝经后妇女或口服避孕药后心血管风险的药物。

  公开号：

  US20030008915A1

文献信息

• Dog coronary artery adenosine receptor. Structure of the N6-aryl subregion
  作者：Shozo Kusachi、Robert D. Thompson、Noboyuki Yamada、Daniel T. Daly、R. A. Olsson

  DOI：10.1021/jm00156a016

  日期：1986.6

  Previous structure-coronary vasoactivity correlations of the N6-alkyladenosine analogues of N6-[(R)-1-phenyl-2-propyl]adenosine, 1, support the hypothesis that the coronary artery A2 adenosine receptor contains an N6 region of specialized structure. The part of this receptor region that binds the 2-propyl moiety of 1 determines stereoselectivity and contributes to coronary vasoactivity. The present study uses 92 adenosine analogues containing an aryl group in the N6 substituent to test the hypothesis that the N6 receptor region contains an aryl subregion that binds the phenyl moiety of 1 and thereby contributes to its coronary vasoactivity. N6-Aralkyladenosines are often more potent than their alkyl congeners. Two methylene residues seem to provide optimum separation of the aryl group from N6. Among adenosines with semirigid N6 substituents, N6-[(1R,2S)-trans-2-phenylcyclohexyl]adenosine was uniquely active, evidence that when 1 occupies the receptor, the axis of the propyl C-1 to phenyl C-1 bond is nearly in the plane described by N6 and propyl C-1 and C-2. The torsion angle around this bond is unknown. Replacing the phenyl group of N6-2-phenethyladenosine with a thienyl or a 3-pyridyl group raises activity. The structure-activity relationships of the N6-(arylethyl)-, the N6-(arylmethyl)-, and the N6-phenyladenosines differ strinkingly from each other. Taken together, such results support the idea that the N6 region of the dog coronary artery A2 adenosine receptor includes an aryl subregion.
• ACYLATED 6,7,8,9-TETRAHYDRO-5H-BENZOCYCLOHEPTENYL AMINES AND THEIR USE AS PHARMACEUTICAL
  申请人：Sanofi-Aventis Deutschland GmbH

  公开号：EP1362027B1

  公开（公告）日：2008-05-21
• US6759412B2
  申请人：——

  公开号：US6759412B2

  公开（公告）日：2004-07-06
• US7709478B2
  申请人：——

  公开号：US7709478B2

  公开（公告）日：2010-05-04
• Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical agents
  申请人：——

  公开号：US20030008915A1

  公开（公告）日：2003-01-09

  The present invention relates to compounds according to the general formula (I), 1 wherein R 1 -R 4 have the meanings given in the description, A is CH 2 , CHOH or CH—(C 1 -C 3 -alkyl), B, C and D are independently CH 2 or CH—(C 1 -C 3 -alkyl), and R 5 is an aryl or heteroaryl group, possibly substituted by the substituents listed in the description. These compounds are useful for the manufacture of medicaments for the treatment of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothelial damage after PTCA, hypertension, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes, diabetes complications, nephropathy, retinopathy, angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, osteoporosis, or restricted memory performance or for a restricted ability to learn, or the lowering of cardiovascular risk of postmenopausal women or after intake of contraceptives.

  本发明涉及符合一般式（I）的化合物，其中R1-R4具有描述中给出的含义，A为CH2，CHOH或CH-（C1-C3-烷基），B、C和D分别为CH2或CH-（C1-C3-烷基），R5为芳基或杂芳基，可能被描述中列出的取代基取代。这些化合物可用于制造治疗心血管疾病、稳定或不稳定性心绞痛、冠心病、普林兹梅塔尔心绞痛、急性冠状动脉综合征、心力衰竭、心肌梗死、中风、血栓形成、周围动脉闭塞性疾病、内皮功能障碍、动脉粥样硬化、再狭窄、PTCA后内皮损伤、高血压、原发性高血压、肺动脉高压、继发性高血压、肾血管性高血压、慢性肾小球肾炎、勃起功能障碍、室性心律失常、糖尿病、糖尿病并发症、肾病、视网膜病变、血管生成、支气管哮喘、慢性肾功能衰竭、肝硬化、或受限的记忆表现或受限的学习能力，或降低绝经后妇女或口服避孕药后心血管风险的药物。